Showing 4621-4630 of 5623 results for "".
- Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy at AAO 2020 Virtualhttps://modernod.com/news/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-at-aao-2020-virtual/2478547/Apellis Pharmaceuticals announced findings from a large retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry was conducted in partnership wit
- Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Studyhttps://modernod.com/news/gemini-therapeutics-announces-gem103-meets-all-endpoints-in-phase-1-clinical-study/2478546/Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-
- Nanoscope Therapeutics Announces Presentation at the 2020 AAOhttps://modernod.com/news/nanoscope-therapeutics-announces-presentation-at-the-2020-aao/2478545/Nanoscope Therapeutics, which is developing ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will be made during the American Academy
- EyeMD EMR 2.0 All-in-One Platform Unveiled at AAO Virtualhttps://modernod.com/news/eyemd-emr-healthcare-systems-to-unveil-the-eyemd-emr-2-0-all-in-one-platform-at-aao-virtual/2478542/EyeMD EMR Healthcare Systems will debut EyeMD EMR 2.0, an all-in-one EMR, PM, and PACS system at the American Academy of Ophthalmology (AAO) Virtual Conference, taking place Nov. 13–15, 2020. EyeMD EMR 2.0 now includes EMR, PM and PACS functionality in one streamlined offering. EyeMD EMR P
- CDC Now Says Wearing a Mask Protects the Wearer, Toohttps://modernod.com/news/cdc-now-says-wearing-a-mask-protects-the-wearer-too/2478538/For months it has been clear that wearing a face mask reduces the transmission of COVID-19, because it prevents your respiratory droplets from spreading and potentially infecting other people. Now the Centers for Disease Control has highlighted another benefit of mask-wearing that many hoped or s
- American Academy of Ophthalmology Leads Global Initiative to Address Worldwide Myopia Epidemichttps://modernod.com/news/american-academy-of-ophthalmology-leads-global-initiative-to-address-worldwide-myopia-epidemic/2478535/The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia, where 80 to 90 percent of chi
- Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on DME at AAO 2020 Virtual Meetinghttps://modernod.com/news/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on-dme-at-aao-2020-virtual-meeting/2478532/Kodiak Sciences announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Details of the presentation are as follows: Event: Late Breaking D
- Zeiss Introduces Video Laryngoscopehttps://modernod.com/news/zeiss-introduces-video-laryngoscope/2478531/With the outbreak of the COVID-19 crisis earlier this year, the Medical Technology segment of Zeiss focused on he
- Gyroscope Therapeutics Announces First Patient Dosed in Phase 2 Trial Evaluating Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-announces-first-patient-dosed-in-phase-2-trial-evaluating-investigational-gene-therapy-for-dry-amd/2478523/Gyroscope Therapeutics announced the initiation of the phase 2 HORIZON trial evaluating GT005 in people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The first patient to receive GT005 in HORIZON was enrolled and dosed in the United States by Jeff
- Leiters and EyeConnect International Announce Corporate Partnershiphttps://modernod.com/news/leiters-and-eyeconnect-international-announce-corporate-partnership/2478520/Leiters, a provider of ophthalmic compounded sterile preparations and pharmacy services, has entered into a partnership with EyeConnect International (ECI) in support of their newly created digital ophthalmic clinical networking platform. Terms of the deal were not disclosed. EyeCon